CoChat

Dispelling the myth: the use of renin-angiotensin blockade in atheromatous renovascular disease

Open access
Chrysochou, C., Foley, R. N., Young, J. F., Khavandi, K., Cheung, C. M., Kalra, P. A. · 2012 · Nephrology Dialysis Transplantation
Cited by 126

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Many physicians retain reservations regarding the routine prescription of renin-angiotensin blockade (RAB) in patients with atheromatous renovascular disease (ARVD). Conversely, these patients are in most need of the cardio- and renal protection offered by RAB. This reservation is mostly because of fear of precipitating acute renal deterioration. We aimed to study whether RAB can be used safely in ARVD patients and whether it altered their outcome. METHODS: Prospective observational study of all ARVD patients presenting to our tertiary referral centre from 1999-2009. Data capture included usage and tolerability of RAB, and correlation with endpoints of cardiovascular events, dialysis or death. RESULTS: Six hundred and twenty-one subjects were available for analysis. Mean age (SD) of the cohort was 71.3 (8.8) years, median (interquartile range) follow-up 3.1 (2.1, 4.8), range 0.2-10.61 years. Seventy-four patients had an intolerance to RAB at study entry. When utilized prospectively, RAB was tolerated in 357 of 378 patients (92%), and this was even seen in 54/69 (78.3%) patients with bilateral>60% renal artery stenosis (RAS) or occlusion. Patients (4/21) who were intolerant of RAB during follow-up (and 12 retrospectively intolerant), underwent renal revascularization which facilitated safe use of these medications post-procedure. On multivariate time-adjusted analysis, patients receiving RAB were significantly less likely to die (P=0.02). CONCLUSION: RAB is well tolerated even in patients with bilateral severe RAS and reduced mortality in a large group of ARVD patients. We recommend all ARVD patients be considered for RAB therapy unless an absolute contra-indication exists. Intolerance of these agents due to renal dysfunction should be considered an emerging indication for renal revascularization to facilitate their re-introduction.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ndt/gfr496

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 35

  1. Kalra, 2010, Kidney international, 77, 37, 10.1038/ki.2009.406 · DOI
  2. 2007, Circulation, 115, 50, 10.1161/CIRCULATIONAHA.106.637751 · DOI
  3. Mailloux, 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation, 24, 622, 10.1016/S0272-6386(12)80223-X · DOI · Paper page
  4. Ihle, 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation, 27, 489, 10.1016/S0272-6386(96)90158-4 · DOI
  5. Casas, 2005, Lancet, 366, 2026, 10.1016/S0140-6736(05)67814-2 · DOI · Paper page
  6. Jafar, 2001, Annals of Internal Medicine, 135, 73, 10.7326/0003-4819-135-2-200107170-00007 · DOI · Paper page
  7. Williams, 2004, Journal of human hypertension, 18, 139, 10.1038/sj.jhh.1001683 · DOI · Paper page
  8. 2003, JAMA, 289, 2560, 10.1001/jama.289.19.2560 · DOI · Paper page
  9. 2005, Journal of the American Society of Nephrology, 16, 2746, 10.1681/ASN.2005010043 · DOI
  10. Harding, 1992, Journal of the American Society of Nephrology, 2, 1608, 10.1681/ASN.V2111608 · DOI · Paper page
  11. de Silva, 2007, The American journal of cardiology, 100, 273, 10.1016/j.amjcard.2007.02.098 · DOI
  12. Makanjuola, 1999, QJM, 92, 515, 10.1093/qjmed/92.9.515 · DOI
  13. The Heart Outcomes Prevention Evaluation Study Inv, 2000, New England Journal of Medicine, 342, 145, 10.1056/NEJM200001203420301 · DOI · Paper page
  14. 2006, Circulation, 114, 26, 10.1161/CIRCULATIONAHA.105.592733 · DOI · Paper page
  15. Goldsmith, 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation, 36, 837, 10.1053/ajkd.2000.17686 · DOI
  16. Burke, 2006, Journal of hypertension, 24, 1193, 10.1097/01.hjh.0000226211.95936.f5 · DOI · Paper page
  17. Franklin, 1985, The American journal of medicine, 79, 14, 10.1016/0002-9343(85)90075-0 · DOI
  18. Mann, 2002, American journal of cardiovascular drugs : drugs, devices, and other interventions, 2, 157, 10.2165/00129784-200202030-00003 · DOI
  19. 2007, Journal of the American College of Cardiology, 50, 2148, 10.1016/j.jacc.2007.08.029 · DOI
  20. Bart, 1997, The American journal of cardiology, 79, 1118, 10.1016/S0002-9149(97)00060-X · DOI
  21. 1996, QJM, 89, 145, 10.1093/qjmed/89.2.145 · DOI
  22. Suresh, 2000, Nephrology Dialysis Transplantation, 15, 631, 10.1093/ndt/15.5.631 · DOI
  23. Kalra, 2005, Kidney international, 68, 293, 10.1111/j.1523-1755.2005.00406.x · DOI · Paper page
  24. MacDowall, 1998, Lancet, 352, 13, 10.1016/S0140-6736(97)11060-1 · DOI · Paper page
  25. Missouris, 1994, The American journal of medicine, 96, 10, 10.1016/0002-9343(94)90109-0 · DOI
  26. 2008, Annals of Internal Medicine, 148, 30, 10.7326/0003-4819-148-1-200801010-00190 · DOI · Paper page
  27. Hricik, 1983, New England Journal of Medicine, 308, 373, 10.1056/NEJM198302173080706 · DOI · Paper page
  28. Ahmed, 2002, Journal of the American Geriatrics Society, 50, 1297, 10.1046/j.1532-5415.2002.50321.x · DOI
  29. van de Ven, 1998, Kidney international, 53, 986, 10.1111/j.1523-1755.1998.00840.x · DOI
  30. 2010, Clinical Journal of the American Society of Nephrology, 5, 623, 10.2215/CJN.07831109 · DOI
  31. 2008, QJM, 101, 519, 10.1093/qjmed/hcn039 · DOI
  32. 2005, Nephrology Dialysis Transplantation, 20, 1604, 10.1093/ndt/gfh865 · DOI · Paper page
  33. Peters, 1998, Kidney international, 54, 1570, 10.1046/j.1523-1755.1998.00164.x · DOI · Paper page
  34. Weinberg, 2004, American journal of nephrology, 24, 340, 10.1159/000078950 · DOI
  35. Khosla, 2006, American journal of therapeutics, 13, 306, 10.1097/00045391-200607000-00005 · DOI

Cited by

See all 126

Metadata

Authors
Chrysochou, C., Foley, R. N., Young, J. F., Khavandi, K., Cheung, C. M., & Kalra, P. A.
Venue
Nephrology Dialysis Transplantation
Published
2011-10-12
Volume
27
Issue
4
Pages
1403-1409
ISSN
  • 0931-0509 (ISSN-L)
  • 1460-2385
OpenAlex
W2164686035
Cited by
126
References
9
FWCI
6.19
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.